Ratings by William Blair (Myles Minter)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/27/2026 | Rapport Therapeutics | RAPP | New Coverage | Outperform (N/A) |
40.68 (48.10) |
18.24% | Details | |
| 3/25/2026 | Ionis Pharmaceuticals | IONS | Maintain | Outperform (N/A) |
|
Details | ||
| 3/19/2026 | Larimar Therapeutics | LRMR | Maintain | Outperform (N/A) |
|
Details | ||
| 3/9/2026 | Xenon Pharmaceuticals | XENE | Maintain | Outperform (N/A) |
|
Details | ||
| 3/2/2026 | Silence Therapeutics | SLN | Maintain | Outperform (N/A) |
|
Details | ||
| 3/2/2026 | Intellia Therapeutics | NTLA | Upgrade | Outperform (Market Perform) |
13.78 (11.94) |
-13.35% | Details | |
| 2/17/2026 | Korro Bio Inc. | KRRO | Upgrade | Outperform (Market Perform) |
11.17 (13.39) |
19.87% | Details | |
| 1/28/2026 | Korro Bio Inc. | KRRO | Maintain | Market Perform (N/A) |
|
Details | ||
| 1/12/2026 | argenx SE | ARGX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/13/2025 | Korro Bio Inc. | KRRO | Downgrade | Market Perform (Outperform) |
31.42 (13.39) |
-57.38% | Details | |
| 11/11/2025 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/5/2025 | Biohaven Pharmaceutical Holding | BHVN | Downgrade | Market Perform (Outperform) |
13.95 (14.34) |
2.8% | Details | |
| 11/5/2025 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Outperform (N/A) |
|
Details | ||
| 10/28/2025 | Intellia Therapeutics | NTLA | Downgrade | Market Perform (Outperform) |
25.60 (13.78) |
-46.17% | Details | |
| 10/27/2025 | NTELOS Holdings | NTLS | Downgrade | Market Perform (Outperform) |
9.26 (9.26) |
0% | Details | |
| 10/22/2025 | Alector Inc. | ALEC | Downgrade | Market Perform (Outperform) |
3.31 (2.07) |
-37.46% | Details | |
| 7/7/2025 | Denali Therapeutics Inc. | DNLI | Maintain | Outperform (N/A) |
|
Details | ||
| 6/30/2025 | Moderna | MRNA | Maintain | Market Perform (N/A) |
|
Details | ||
| 6/23/2025 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 6/18/2025 | Contineum Therapeutics | CTNM | New Coverage | Outperform (N/A) |
3.93 (15.96) |
306.11% | Details | |
| 6/17/2025 | Verve Therapeutics | VERV | Downgrade | Market Perform (Outperform) |
6.27 (11.13) |
77.51% | Details | |
| 5/22/2025 | Vigil Neuroscience Inc | VIGL | Downgrade | Market Perform (Outperform) |
2.31 (8.05) |
248.48% | Details | |
| 4/25/2025 | Xenon Pharmaceuticals | XENE | New Coverage | Outperform (N/A) |
37.59 (64.30) |
71.06% | Details | |
| 4/25/2025 | Vigil Neuroscience Inc | VIGL | New Coverage | Outperform (N/A) |
1.81 (2.31) |
27.62% | Details | |
| 4/25/2025 | Ovid Therapeutics Inc | OVID | New Coverage | Outperform (N/A) |
0.33 (2.87) |
769.7% | Details | |
| 4/25/2025 | Denali Therapeutics Inc. | DNLI | New Coverage | Outperform (N/A) |
14.87 (25.32) |
70.28% | Details | |
| 4/25/2025 | Biohaven Pharmaceutical Holding | BHVN | New Coverage | Outperform (N/A) |
21.42 (13.95) |
-34.87% | Details | |
| 4/25/2025 | Alector Inc. | ALEC | New Coverage | Outperform (N/A) |
1.16 (3.31) |
185.34% | Details | |
| 3/25/2025 | Entrada Therapeutics | TRDA | Maintain | Outperform (N/A) |
|
Details | ||
| 3/25/2025 | Immunic Inc. | IMUX | New Coverage | Outperform (N/A) |
1.15 (16.57) |
1340.87% | Details | |
| 11/1/2024 | argenx SE | ARGX | Upgrade | Outperform (Market Perform) |
551.71 (863.44) |
56.5% | Details | |
| 8/14/2024 | Korro Bio Inc. | KRRO | New Coverage | Outperform (N/A) |
36.36 (31.42) |
-13.59% | Details | |
| 12/22/2023 | Karuna Therapeutics Inc. | KRTX | Downgrade | Market Perform (Outperform) |
215.19 (329.83) |
53.27% | Details | |
| 12/14/2023 | Reneo Pharmaceuticals | RPHM | Downgrade | Market Perform (Outperform) |
7.75 (1.82) |
-76.52% | Details | |
| 11/15/2023 | Reneo Pharmaceuticals | RPHM | New Coverage | Outperform (N/A) |
6.25 (1.82) |
-70.88% | Details | |
| 7/24/2023 | Moderna | MRNA | New Coverage | Market Perform (N/A) |
126.43 (64.06) |
-49.33% | Details | |
| 5/30/2023 | Vertex | VRTX | New Coverage | Outperform (N/A) |
329.99 (525.28) |
59.18% | Details | |
| 3/6/2023 | Praxis Precision Medicines Inc. | PRAX | Downgrade | Market Perform (Outperform) |
1.00 (380.06) |
37906% | Details | |
| 9/19/2022 | Larimar Therapeutics | LRMR | Upgrade | Outperform (Market Perform) |
3.20 (4.26) |
33.13% | Details | |
| 6/7/2022 | Alnylam Pharmaceuticals | ALNY | New Coverage | Outperform (N/A) |
131.63 (226.28) |
71.91% | Details | |
| 4/7/2022 | Aptinyx | APTX | Downgrade | Market Perform (Outperform) |
2.34 (0.06) |
-97.44% | Details | |
| 2/15/2022 | Larimar Therapeutics | LRMR | Downgrade | Market Perform (Outperform) |
8.37 (4.26) |
-49.1% | Details | |
| 12/14/2021 | Ionis Pharmaceuticals | IONS | Upgrade | Outperform (Market Perform) |
30.17 (55.89) |
85.25% | Details | |
| 9/27/2021 | Alector Inc. | ALEC | New Coverage | Outperform (N/A) |
23.60 (2.07) |
-91.23% | Details | |
| 4/26/2021 | Praxis Precision Medicines Inc. | PRAX | New Coverage | Outperform (N/A) |
27.93 (380.06) |
1260.76% | Details | |
| 2/1/2021 | Larimar Therapeutics | LRMR | New Coverage | Outperform (N/A) |
15.71 (4.26) |
-72.88% | Details | |
| 2/1/2021 | Limoneira Company | LMNR | New Coverage | Outperform (N/A) |
15.97 (13.92) |
-12.84% | Details | |
| 5/8/2020 | Aptinyx | APTX | New Coverage | Outperform (N/A) |
3.65 (0.06) |
-98.36% | Details | |
| 12/30/2019 | Axsome Therapeutics | AXSM | Maintain | Outperform (N/A) |
|
Details | ||
| 12/12/2019 | Karuna Therapeutics Inc. | KRTX | New Coverage | Outperform (N/A) |
64.42 (329.83) |
412% | Details | |
| 9/18/2019 | Axsome Therapeutics | AXSM | New Coverage | Outperform (N/A) |
29.16 (217.88) |
647.19% | Details |
